BioVie to host KOL event on Phase 2 study of bezisterim

BioVie (BIVI) will host a virtual key opinion leader event featuring Suzanne de la Monte, MD, MPH and Mark Stacy, MD, who will join company management to discuss the unmet need and current treatment landscape for Parkinson’s disease on Wednesday, May 28, 2025 at 12:00 PM ET. The event will provide an update on BioVie’s Phase 2 trial evaluating bezisterim for the treatment of Parkinson’s disease. Bezisterim is a novel, orally-administered small molecule that has been shown to reverse insulin resistance and selectively inhibit inflammation-driven ERK- and NF-B-stimulated inflammatory mediators without inhibiting their homeostatic functions. Inflammation and the associated insulin resistance are important to the presentation of Parkinson’s symptoms. BioVie is currently enrolling patients recently diagnosed with Parkinson’s disease who have not yet begun treatment in order to measure bezisterim’s potential impact on clinical signs and effects on biomarkers that may correlate with disease-modification for the SUNRISE-PD trial.